Latest News and Press Releases

Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of...

Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II...

Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage...

Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic...

Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast...

Media Release Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April ...

Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for...

Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti will be studied in neoadjuvant, non-metastatic cancer settingNovel...